Filtered By:
Source: Translational Oncology
Drug: Velcade
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB
Transl Oncol. 2021 May 8;14(8):101114. doi: 10.1016/j.tranon.2021.101114. Online ahead of print.ABSTRACTAcross many cancer types in adults, upregulation of the nuclear-to-cytoplasmic transport protein Exportin-1 (XPO1) correlates with poor outcome and responsiveness to selinexor, an FDA-approved XPO1 inhibitor. Similar data are emerging in childhood cancers, for which selinexor is being evaluated in early phase clinical studies. Using proteomic profiling of primary tumor material from patients with high-risk neuroblastoma, as well as gene expression profiling from independent cohorts, we have demonstrated that XPO1 overexp...
Source: Translational Oncology - May 11, 2021 Category: Cancer & Oncology Authors: Basia Galinski Marcus Luxemburg Yosef Landesman Bruce Pawel Katherine J Johnson Stephen R Master Kevin W Freeman David M Loeb Jean M H ébert Daniel A Weiser Source Type: research
